Journal of Clinical and Experimental Hepatology | 2021
A Current Understanding of Bile Acids in Chronic Liver Disease
Abstract
Abstract Chronic liver disease (CLD) is one of the leading causes of Disability-adjusted life years (DALYs) in many countries. A recent understanding of nuclear bile acid receptor pathways has increased focus on the impact of crosstalk between the gut, bile acids, and liver on liver pathology. While conventionally used in cholestatic disorders and to dissolve gallstones, the discovery of bile acids’ influence on the gut microbiome and human metabolism offers a unique potential for their utility in early and advanced liver diseases due to diverse etiologies. Based on these findings, pre-clinical studies using bile acid-based molecules have shown encouraging results at addressing liver inflammation and fibrosis. Emerging data also suggests that bile acid profiles change distinctively across various causes of liver disease. We summarize the current knowledge and evidence related to bile acids in health and disease and discuss culminated and ongoing therapeutic trials of bile acid derivatives in chronic liver disease. In the near future, further evidence in this area might help clinicians better detect and manage liver diseases.